Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
or

Arcutis Biotherapeutics Inc (ARQT)

Arcutis Biotherapeutics Inc (ARQT)
12.50 x 2 13.84 x 1
Post-market by (Cboe BZX)
13.01 +0.05 (+0.39%) 04/17/25 [NASDAQ]
12.50 x 2 13.84 x 1
Post-market 13.26 +0.25 (+1.92%) 18:11 ET
Quote Overview for Thu, Apr 17th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
12.75
Day High
13.86
Open 12.96
Previous Close 12.96 12.96
Volume 1,598,300 1,598,300
Avg Vol 2,584,500 2,584,500
Stochastic %K 21.42% 21.42%
Weighted Alpha +25.38 +25.38
5-Day Change -0.43 (-3.20%) -0.43 (-3.20%)
52-Week Range 6.99 - 17.75 6.99 - 17.75
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,543,481
  • Shares Outstanding, K 118,638
  • Annual Sales, $ 196,540 K
  • Annual Income, $ -140,040 K
  • EBIT $ -128 M
  • EBITDA $ -133 M
  • 60-Month Beta 1.67
  • Price/Sales 7.82
  • Price/Cash Flow N/A
  • Price/Book 9.63

Options Overview Details

View History
  • Implied Volatility 77.33% ( +5.41%)
  • Historical Volatility 79.68%
  • IV Percentile 16%
  • IV Rank 22.41%
  • IV High 177.18% on 07/18/24
  • IV Low 48.49% on 10/09/24
  • Put/Call Vol Ratio 0.20
  • Today's Volume 434
  • Volume Avg (30-Day) 1,144
  • Put/Call OI Ratio 0.29
  • Today's Open Interest 23,448
  • Open Int (30-Day) 19,742

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.19
  • Number of Estimates 4
  • High Estimate -0.10
  • Low Estimate -0.22
  • Prior Year -0.32
  • Growth Rate Est. (year over year) +40.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.86 +9.70%
on 04/11/25
Period Open: 16.42
17.75 -26.70%
on 03/25/25
-3.41 (-20.77%)
since 03/17/25
3-Month
11.13 +16.89%
on 02/11/25
Period Open: 12.68
17.75 -26.70%
on 03/25/25
+0.33 (+2.60%)
since 01/17/25
52-Week
6.99 +86.12%
on 06/10/24
Period Open: 10.25
17.75 -26.70%
on 03/25/25
+2.76 (+26.93%)
since 04/17/24

Most Recent Stories

More News
Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025

ARQT : 13.01 (+0.39%)
Arcutis Announces Chief Financial Officer Transition

ARQT : 13.01 (+0.39%)
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ARQT : 13.01 (+0.39%)
Arcutis and Padagis Agree to Stay Patent Lawsuit

ARQT : 13.01 (+0.39%)
Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference

ARQT : 13.01 (+0.39%)
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting

ARQT : 13.01 (+0.39%)
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ARQT : 13.01 (+0.39%)
Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting

ARQT : 13.01 (+0.39%)
U.S. FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis 

ARQT : 13.01 (+0.39%)
Arcutis Biotherapeutics Sees 400% Spike In Retail Buzz As Q4 Beat Fuels After-Hours Rally

Sales of Zoryve, Arcutis' leading dermatology drug, surged 413% year-over-year to $69.4 million, a 55% increase from the previous quarter.

ARQT : 13.01 (+0.39%)
VTI : 258.75 (+0.21%)
IWM : 186.48 (+0.82%)
XBI : 75.93 (+1.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Arcutis Biotherapeutics Inc. is late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases. The company's product pipeline consists of ARQ-151, ARQ-154 and ARQ-252 for multiple indications, including psoriasis,...

See More

Key Turning Points

3rd Resistance Point 14.77
2nd Resistance Point 14.32
1st Resistance Point 13.66
Last Price 13.01
1st Support Level 12.55
2nd Support Level 12.10
3rd Support Level 11.44

See More

52-Week High 17.75
Fibonacci 61.8% 13.64
Last Price 13.01
Fibonacci 50% 12.37
Fibonacci 38.2% 11.10
52-Week Low 6.99

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro